Belite Bio (BLTE) Preferred Stock Liabilities (2020 - 2021)
Belite Bio (BLTE) posted quarterly Preferred Stock Liabilities of $31.8 million for Q4 2021, little changed year-over-year from $31.8 million in Q4 2020, and little changed quarter-over-quarter from $31.8 million in Q4 2020.
Powered by 
Analysis
Belite Bio (BLTE) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Belite Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $31.8 million for Q4 2021.
- In Q4 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $31.8 million; the TTM figure through Dec 2021 stood at $31.8 million (changed 0.0% YoY), while the FY2021 annual figure was $31.8 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q4 2021 stood at $31.8 million, roughly flat from $31.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $31.8 million in Q4 2020, with the low at $31.8 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Belite Bio | 6.25 Bn | 6.25 Bn | - | - |